- Home
- IGI vs PROK Comparison
IGI vs PROK Comparison
Compare IGI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGI | PROK |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.4M | 316.0M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IGI | PROK |
|---|---|---|
| Price | $15.80 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 9.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $15.56 | $1.30 |
| 52 Week High | $17.09 | $3.48 |
Technical Indicators
Market Signals| Indicator | IGI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 32.19 | 55.81 |
| Support Level | $15.56 | $1.73 |
| Resistance Level | $16.33 | $1.96 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 0.00 | 61.36 |
Price Performance
Historical ComparisonAbout IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.